Ahmad, Jawad http://orcid.org/0000-0003-1384-2349
Odin, Joseph A.
Hayashi, Paul H.
Chalasani, Naga
Fontana, Robert J.
Barnhart, Huiman
Cirulli, Elizabeth T.
Kleiner, David E.
Hoofnagle, Jay H.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (U01DK100928)
Article History
Received: 25 July 2017
Accepted: 16 October 2017
First Online: 8 November 2017
Compliance with ethical standards
:
: Dr. Chalasani has ongoing consulting activities (or had in the preceding 12 months) with NuSirt, Abbvie, Eli Lilly, Afimmune (DS Biopharma), Tobira (Allergan), Madrigal, Shire, Cempra, Ardelyx, Gen Fit and Amarin. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Dr. Chalasani receives research grant support from Intercept, Lilly, Gilead, Galectin Therapeutics and Cumberland where his institution receives the funding. Over the last decade, Dr. Chalasani has served as a paid consultant to more than 30 pharmaceutical companies, and these outside activities have regularly been disclosed to his institutional authorities. Drs. Kleiner and Hoofnagle have no conflicts of interest to disclose.
Free to read: This content has been made available to all.